Current Rating Overview
MarketsMOJO currently assigns Anuh Pharma Ltd a 'Sell' rating, reflecting a cautious stance on the stock. This rating was revised on 04 Feb 2026, when the company’s Mojo Score improved from 26 to 40 points, moving the grade from 'Strong Sell' to 'Sell'. Despite this improvement, the recommendation suggests that investors should remain wary of the stock’s near-term prospects given prevailing market and company-specific factors.
Quality Assessment
As of 21 March 2026, Anuh Pharma’s quality grade is assessed as average. The company’s long-term growth has been modest, with net sales expanding at an annualised rate of 13.54% over the past five years, while operating profit grew at 11.42% annually. These figures indicate steady but unspectacular growth, which may not be sufficient to justify a more optimistic rating in a competitive pharmaceuticals and biotechnology sector.
The return on capital employed (ROCE) for the half-year ended December 2025 stands at a relatively low 15.90%, signalling limited efficiency in generating profits from capital invested. Additionally, cash and cash equivalents are at a low ₹2.15 crores, which may constrain the company’s ability to fund growth initiatives or weather market volatility.
Valuation Perspective
Currently, the valuation grade for Anuh Pharma is considered fair. While the microcap status of the company often entails higher risk and volatility, the stock’s price does not appear excessively stretched relative to its earnings and asset base. However, the absence of significant institutional interest, particularly from domestic mutual funds which hold 0% of the company, suggests a lack of confidence from professional investors who typically conduct thorough due diligence.
This lack of institutional backing may reflect concerns about the company’s growth trajectory or valuation, signalling that the market is pricing in considerable uncertainty. Investors should weigh this carefully when considering exposure to Anuh Pharma.
Financial Trend Analysis
The financial trend for Anuh Pharma is currently flat, indicating limited momentum in improving profitability or operational efficiency. The company’s recent results for December 2025 showed no significant growth, reinforcing the view that the business is in a holding pattern rather than on a clear upward trajectory.
Stock returns as of 21 March 2026 further illustrate this subdued performance. The stock has declined by 0.59% in the past day, 3.90% over the past week, and 1.34% in the last month. More notably, the six-month return stands at -15.55%, with a year-to-date loss of 7.93% and a one-year return of -4.94%. These figures highlight the challenges the stock faces in delivering positive returns to shareholders in the current market environment.
Technical Outlook
The technical grade for Anuh Pharma is mildly bearish, reflecting recent price trends and market sentiment. The stock’s downward momentum over multiple time frames suggests that short-term technical indicators are not favourable. This bearish technical stance supports the 'Sell' rating, signalling that investors may want to exercise caution and consider risk management strategies if holding the stock.
Implications for Investors
For investors, the 'Sell' rating on Anuh Pharma Ltd indicates that the stock is currently expected to underperform relative to the broader market or sector peers. The combination of average quality, fair valuation, flat financial trends, and mildly bearish technicals suggests limited upside potential and elevated risk. Investors should carefully assess their risk tolerance and portfolio objectives before considering exposure to this microcap pharmaceutical company.
It is important to note that while the rating was updated on 04 Feb 2026, all financial data and returns referenced here are current as of 21 March 2026, ensuring that the analysis reflects the latest available information.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, companies are often evaluated on their innovation pipeline, regulatory approvals, and market penetration. Anuh Pharma’s microcap status and modest growth rates place it at a disadvantage compared to larger peers with stronger research and development capabilities and broader market reach.
Moreover, the absence of domestic mutual fund participation may indicate that professional investors are prioritising other opportunities within the sector that offer better growth prospects or more attractive valuations. This dynamic further underscores the need for caution when considering Anuh Pharma as an investment.
Conclusion
In summary, Anuh Pharma Ltd’s 'Sell' rating by MarketsMOJO reflects a comprehensive evaluation of its current fundamentals, valuation, financial trends, and technical outlook. While the company has shown some improvement from a 'Strong Sell' grade earlier this year, the prevailing conditions suggest that the stock remains a cautious proposition for investors.
Investors should monitor the company’s future earnings reports, cash flow developments, and sector dynamics closely to reassess the stock’s potential. Until then, the 'Sell' rating advises prudence and careful consideration of risk exposure in portfolios.
Key Metrics Summary as of 21 March 2026:
- Mojo Score: 40.0 (Sell Grade)
- Market Capitalisation: Microcap
- Quality Grade: Average
- Valuation Grade: Fair
- Financial Grade: Flat
- Technical Grade: Mildly Bearish
- ROCE (HY): 15.90%
- Cash & Cash Equivalents (HY): ₹2.15 crores
- 1-Year Stock Return: -4.94%
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
